According to the Zhitong Finance App, Lai Kai Pharmaceutical-B (02105.HK) announced that the Group has initiated the recruitment of subjects for the LAE118 Phase I clinical study (“Phase I Clinical Study”) for the treatment of advanced solid tumors in China, and has completed the enrollment of the first test subjects.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.